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ediatric Cardiac Interventions
iyad M. Hijazi, MD, MPH, FACC, Sawsan M. Awad, MD
hicago, Illinois
he ﬁeld of pediatric cardiac interventions has witnessed a dramatic increase in the number and type
f procedures performed. We review the most common procedures performed in the catheter labora-
ory. Lesions are divided according to their physiological characteristics into left-to-right shunting le-
ions (atrial septal defect, patent ductus arteriosus, ventricular septal defect), right-to-left shunting le-
ions (pulmonary stenosis, pulmonary atresia/intact ventricular septum), right heart obstructive lesions
peripheral arterial pulmonic stenosis, right ventricular outﬂow tract obstruction), and left heart ob-
tructive lesions (aortic valve stenosis, coarctation of the aorta). In addition, a miscellaneous group of
esions is discussed. (J Am Coll Cardiol Intv 2008;1:603–11) © 2008 by the American College of
ardiology FoundationL
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fn the past 2 to 3 decades, the field of pediatric
nterventional cardiology has experienced signifi-
ant growth. Technological innovations have
reatly advanced treatment of cardiovascular dis-
ase in both children and adults with congenital
eart disease (CHD). Interventional therapy has
ecome an acceptable alternative treatment for
any CHD, including closure of atrial defects,
uscular ventricular septal defects (VSDs), patent
uctus arteriosus (PDA), dilation of stenotic valves
aortic and pulmonary), and dilation of stenotic
essels (branch pulmonary arteries, coarctation of
he aorta [COA]). In some cases where the percu-
aneous approach is difficult or the patient still
equires repair of other associated cardiac anoma-
ies, a hybrid approach can be implemented with its
bvious advantages to the patient.
In this article, we will review the advances and
tate-of-the-art in interventional therapy for
HD. For the best understanding of the various
esions that can be treated in the catheterization
aboratory, we will attempt to divide the lesions
ased on their physiological characteristics.
rom the Rush Center for Congenital and Structural Heart Disease and
he Section of Cardiology, Department of Pediatrics, Rush University
edical Center, Chicago, Illinois.(
anuscript received April 14, 2008; revised manuscript received June 24,
008, accepted July 27, 2008.eft-to-Right Shunting Lesions
trial level shunts, such as atrial septal defect
ASD) and patent foramen ovale, are common
ongenital cardiac defects. Because patent foramen
vale is quite common and there is still controversy
bout closure in patients who sustain a cryptogenic
troke, we elected not to discuss it in this article.
Atrial septal defects account for approximately
9% of all CHD (1). With the advances in diag-
ostic tools for CHD, the incidence of many of the
efects has increased compared with reports from
he past (2).
Patients with ASDs are usually asymptomatic in
he first 2 decades of life. Usually, if the Q p/Q s
atio is more than 1.5:1, such patients may expe-
ience symptoms of shortness of breath and fatigue
3). As shunting continues, there are risks of
evelopment of right ventricular volume overload
nd later dysfunction, progressive pulmonary vas-
ular disease, and atrial arrhythmias. In addition,
hese patients are at risk of development of para-
oxical embolus (3–5). In 1974, King and Mills (6)
erformed the first successful transcatheter closure
f a secundum ASD. After that, a number of
ifferent devices were developed with variable de-
rees of success (7–11). The currently approved
evices by the U.S. Food and Drug Administration
or clinical use are the Amplatzer septal occluder
ASO) (AGA Medical, Plymouth, Minnesota),
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604nd the Helex septal occluder (W. L. Gore and Associates,
lagstaff, Arizona).
The ASO provides good closure rates (97%) with similar
r lower complication rates than open-heart surgery (12,13).
The Helex septal occluder consists of an expanded
olytetrafluoroethylene patch material with hydrophilic
oating, supported by a nickel-titanium (nitinol) superelas-
ic wire frame in the shape of a coil. This device is not
uitable for defects larger than 18 mm (14).
Various modifications of the ASO have been reported,
ncluding fenestrated ASO and the cribriform ASO for
ultifenestrated ASDs or ASDs with septal aneurysms
15,16). We prefer the use of intracardiac echocardiography
o guide closure of ASD, even in smaller children (17).
igure 1 demonstrates steps of closure of a large ASD using
SO under intracardiac echocardiography guidance.
Ventricular septal defects are considered the most com-
mon cardiac abnormalities found
in children, accounting for ap-
proximately 30% of all defects
(1,18). Ventricular septal defects
could be classified into 4 major
categories according to Soto et
al. (19) with the perimembra-
nous category being the most
common representing type fol-
lowed by the muscular defects. A
VSD can rarely be iatrogenic
secondary to traumatic injury to
the chest and in 0.2% of patients
following ventricular septal rup-
ture associated with myocardial
infarction. Large VSDs are un-
likely to close spontaneously,
and patients with such defects
will present with signs and
symptoms of congestive heart
ailure and failure to thrive. All VSDs can be repaired
urgically with the exception of the apical defects and Swiss
heese–type of VSD. The latter consists of multiple apical
uscular VSDs due perhaps to excessive resorption of
yocardial tissue during formation of the muscular part of
he interventricular septum. The overall risk for VSD repair
s less than 5%. Mortality and morbidity rates increase with
ultiple VSDs, pulmonary hypertension, residual VSD, and
omplex associated anomalies. Complete heart block imme-
iately after surgery occurs in less than 1% of patients.
ate-onset complete heart block is occasionally a problem,
specially in patients who have a post-operative complete right
undle branch block with a left anterior hemiblock (20,21).
Since the first successful percutaneous VSD device clo-
ure in 1987 by Lock et al. (22), there have been several
eports of transcatheter closure of the VSD using different
bbreviations
nd Acronyms
DO  Amplatzer duct
ccluder
S  aortic valve stenosis
SD  atrial septal defect
SO  Amplatzer septal
ccluder
HD  congenital heart
isease
OA  coarctation of the
orta
DA  patent ductus
rteriosus
S  pulmonary stenosis
SD  ventricular septal
efectevices (23–28). The Amplatzer muscular occluder device pAGA Medical) was specifically designed for the ventricular
eptum. It is made of 0.004- to 0.005-inch nitinol wire.
olzer et al. (29) reported on the use of this device in a U.S.
egistry. Their data were prospectively collected from 83
rocedures involving 75 patients who underwent an attempt
f percutaneous and/or perventricular device closure of
emodynamically significant muscular VSDs. The device
as implanted successfully in 86.7% procedures. Complete
losure was achieved in 47.2% at 24 h, which increased to
9.6% at 6 months and to 92.3% at 12 months follow-up.
igure 2 shows a patient’s muscular VSD after closure with
device.
In smaller patients (less than 5 kg) and patients with
bnormal septal planes (e.g., double outlet right ventricle,
ransposition of the great vessels) or patients with other
ssociated cardiac defects requiring repair, the hybrid ap-
roach has been advocated as an alternative to conventional
urgery on cardiopulmonary bypass (30).
Percutaneous transcatheter closure of perimembranous
SDs using the Amplatzer membranous VSD occluder
AGA Medical) has recently become available as well. This
evice has a unique design with a left ventricular desk that
s asymmetric (31). However, the complication rate using
his device is more than that of the surgical closure,
specially the incidence of complete heart block (32,33).
ue to the high incidence of complete heart block, clinical
rials in the U.S. using this device have been terminated.
Patent ductus arteriosus is the presence of the normal
etal structure commonly connecting between the left pul-
onary artery and the descending aorta beyond 2 to 3 weeks
f life and represents 5% to 10% of all CHD, excluding
hose in premature infants (34).
In infants beyond the neonatal period, device and or coil
losure has been advocated since the 1980s (4).
The Amplatzer duct occluder (ADO) is currently the
ost commonly used device with a low rate of procedure- or
evice-related complications (35). Figure 3 demonstrates
losure in a child with PDA.
Modifications of the ADO device have taken place to
vercome certain technical difficulties. The angled ADO was
eveloped to overcome the protrusion of the original device in
he aortic lumen of smaller children causing partial aortic
bstruction (36,37). However, the manufacturer never pursued
his device. Another modification to the original device is the
DO-II (AGA Medical), which has a cylindrical waist with
etention disks on either end to secure it in the PDA. This
evice is currently under clinical trials in the U.S.
The Nit-Occlud PDA system (Pfm Medical, Oceanside,
alifornia) was used by Celiker et al. (38) in 2005 to close
oderate-size PDA.
Coronary arteriovenous fistulae can originate from all
ajor epicardial coronary arteries, and drainage usually
ccurs to the coronary sinus, right atrium, right ventricle, or
ulmonary artery. These collaterals can become markedly
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605nlarged and can lead to significant left-to-right shunting
ith right-sided volume overload and effective coronary
rterial steal leading to ischemia (3). Coils and devices have
een used to close clinically significant fistulae. The ASD
losure devices and the ADO have been used successfully.
Complications associated with catheter closure of such
stulae include transient ischemic episodes, device emboli-
ation to various chambers/vessels, myocardial infarction,
nd transient atrial arrhythmias (39,40).
Figure 1. Intracardiac Echocardiographic Images During Transcatheter Clo
(A, B) Images in septal view without (A) and with (B) color Doppler, demonstr
long axis (caval) view without (C) and with (D) color Doppler, demonstrating t
(E) and with (F) color Doppler, demonstrating the large defect (arrow) measu
short-axis (H) view, demonstrating good device position and no residual sh
atrium; SVC  superior vena cava.
Figure 2. Cine Fluoroscopic Images in a 6-Year-Old Female Child With High
(A) Angiogram in the left ventricle in the long axial oblique view (long axial o
(arrow) that measured about 6 mm. (B) Repeat left ventricle angiogram after
sure and good device position.Aortopulmonary windows are rare forms of CHD (41).
arge defects are usually closed surgically. If the defect is
mall, percutaneous device closure may be feasible (42,43).
ight-to-Left Shunting Lesions
solated valvular pulmonary stenosis (PS) represents 80% to
0% of all patients with right ventricular outflow tract
bstruction, and 8% to 10% of all patients with CHD. The
f a Large Secundum ASD in a 12.5-Year-Old Male Child
the presence of a large defect (arrow) measuring 31 mm. (C, D) Images in
ge defect (arrow) measuring 26 mm. (E, F) Images in short-axis view without
4 mm. (G, H) Images after a 34-mm device was implanted in caval (G) and
SD  atrial septal defect; AV  aortic valve; LA  left atrium; RA  right
ular VSD
: 50°, cranial: 15°) showing a high muscular ventricular septal defect (VSD)
ment of a 8-mm Amplatzer muscular VSD occluder showing complete clo-sure o
ating
he lar
ring 2
unt. AMusc
blique
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606tenotic valve is usually dome-shaped, with diffuse thicken-
ng and commissural fusion.
With systemic and suprasystemic right ventricular pres-
ure, right-to-left shunt occurs at the atrial level, and this
ay lead to cyanosis. Patients with mild PS are usually
symptomatic. Indications for treatment include symptom-
tic patients, asymptomatic patients with severe PS (gradi-
nt 80 mm Hg), or evidence of right ventricular hyper-
rophy. Balloon pulmonary valvuloplasty was initially
escribed in children by Kan et al. (44). The success rates
re excellent for children with classical PS; however, for
atients with dysplastic valves or with supravalvular and or
ubvalvular PS, the success rate is low (7).
In selected infants with membranous pulmonary atresia
nd adequately sized right ventricle, perforation of the
embrane with either the stiff end of a wire or using
adiofrequency perforation followed by balloon dilation has
een successful in creating an open right ventricular outflow
Figure 3. Cine Fluoroscopic Images in the Lateral Projection in a 6.5-Year-
(A) Angiogram in the descending aorta demonstrating a 2-mm patent ductus
delivery sheath across the PDA into the descending aorta with the device nea
part of a 6- to 4-mm Amplatzer duct occluder (arrow). (D) Final angiogram afract. The radiofrequency technique is promising, but it has ahe risk of inadvertent perforation of the right ventricular
utflow tract (45,46).
In cases of pulmonary atresia with intact ventricular
eptum, right-to-left shunt occurs at the atrial level. After
onstruction of the right ventricular outflow tract in such
esions, device closure of the atrial communication may be
dvised. In these cases, temporary test occlusion of the atrial
ommunication with a balloon may be necessary before
evice closure depending on the hemodynamic response. If
he right atrial pressure does not increase significantly from
aseline (no more than 5-mm Hg mean increase) with
table blood pressure, then device closure of the defect can
e carried out using a device at least 2 to 4 mm larger than
he “balloon stretched diameter” of the defect.
Right-to-left shunt across the atrial level communication
s found in certain lesions. In some forms of complex CHD,
he presence of unrestrictive atrial communication is crucial
or survival of patients with such defects until palliative
male Child With a PDA
sus (PDA) at its narrowest diameter (arrow), angiographic type A. (B) 6-F
ip of the sheath (arrow). (C) Deployment of the retention desk and tubular
device has been released, demonstrating complete closure of the ductus.Old Fe
arterio
r the tnd/or corrective surgeries take place. Right-to-left shunt-
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607ng across the atrial septum is essential in certain congenital
eart defects. An example of this is in patients with
ricuspid and/or pulmonary atresia with intact ventricular
eptum. Patients with hypoplastic left heart syndrome
equire decompression of their hypertensive left atrium if
he septum is intact or restrictive. Post-operative Fontan
atients with low cardiac output may require a fenestration
n the Fontan circuit to allow right-to-left shunting. Further,
ome patients may require mixing at the atrial level to enhance
heir systemic saturation (patients with d-transposition). There
re multiple techniques to create an atrial septal defect
nd/or dilate a restrictive, already present, defect. In 1966,
ashkind and Miller (47) first described balloon atrial
eptostomy as palliation for patients with transposition of
he great arteries to improve saturation. In 1996, Coe et al.
48) first reported the use of cutting balloons to create an
trial communication in piglets. The technique proved to be
ffective in creating adequately sized atrial septal commu-
ication. Later, this technique was used to create atrial
ommunication after septal perforation or radiofrequency
eptal perforation in cases of thickened intact atrial septum
49). Park et al. (50) first described blade atrial septostomy.
his procedure is recommended for older patients (6 to 8
eeks) where the presence of an adequate atrial septal
ommunication is crucial to patient survival.
Atrial communication may be needed for short- or
ong-term palliation. Patients with pulmonary hypertension
r a failed Fontan procedure will require the communication
n a long-term basis. In such cases, stenting of the defect
ay afford long-term palliation (51).
eft-Sided Obstructive Lesions
alvular aortic valve stenosis (AS) occurs in approximately
% to 6% of patients with CHD (1,52). The stenotic valve
s usually secondary to increased thickening and rigidity of
he valve tissue and variable degrees of commissural fusion.
s stenosis progresses, hypertrophy increases. With severe
ypertrophy and valvular obstruction, myocardial ischemia
ay result from the combination of limited cardiac output,
educed coronary perfusion, and increased myocardial oxy-
en consumption.
In neonatal critical AS (left ventricular outflow tract
bstruction at valvular level, which presents in the first few
ays of life and is a duct-dependent lesion), congestive heart
ailure and shock occurs around the time of natural PDA
losure. In older children, the presentation could be the
ystolic ejection murmur characteristic for valvular AS.
Indications for intervention include neonates with critical
S irrespective of the gradient and infants and children with
eak-to-peak gradient across the valve of more than 55 mm
g (53). Aortic valvuloplasty for congenital AS is a safeechnique with a reported incidence of complications of 3% v54,55). The initial balloon chosen for the valvuloplasty should
e 85% to 90% of the aortic valve annulus measured via aortic
ngiography. Optimal results from the procedure should
chieve 50% or more reduction in the gradient with no increase
n aortic regurgitation. If a nonsatisfactory result is encountered
nd no significant increase in aortic regurgitation is noticed, a
arger balloon diameter can be used to repeat the procedure.
Coarctation of the aorta accounts for 5% to 8% of all
HD (1). It is more common in males than females. There
s a high incidence, 15% to 20%, of COA in patients with
urner syndrome. Surgery had been the standard therapy
or COA until Sos et al. (56) in 1979 showed that excised
egments of coarcted aorta could be dilated. After that, the
echnique was used and modified, and the results were
eported (57–59). Indications for balloon dilation of COA
re basically the same as those for surgery, which include
ypertension proximal to the coarctation with a resting
ystolic pressure gradient across the narrowed segment
20 mm Hg or angiographically severe coarctation with
xtensive collaterals (53). There is controversy about balloon
ilation of native COA due to the risk of aneurysm
ormation after angioplasty. Some believe that angioplasty
hould only be performed on cases of recoarctation; others
dvocate its use in both native and recurrent coarctation
60). The use of lower profile sheaths and balloons leads
o marked improvement in the angioplasty results. Some
atients who had their COA repaired surgically early in life
evelop recurrent or residual COA (61,62). Balloon angio-
lasty is a preferable alternative to surgery for treatment of
ecoarctation of the aorta with good acute results and low
omplication rates (63). Endovascular stent implantation
as become an accepted modality for treatment of native
nd recurrent coarctation of the aorta in children and adults
64–66). In recent years, balloon-expandable stents mounted
n a balloon dilation catheter serve as endovascular prostheses
hat maintain patency of the stenotic vessels and vascular
hannels. The Palmaz balloon-expandable stents (Johnson
Johnson, Warren, New Jersey) are the most commonly
sed in the pediatric age group. Figure 4 shows a child’s
OA that was successfully treated with a stent placement.
The most common abnormalities/complications usually
ncountered following intravascular stent placement are the
evelopment of an aneurysm and intimal proliferation
ithin the stent (64,67–70). Although covered stents are
seful in the management of certain patients with coarcta-
ion, aneurysm formation may still occur in patients with
ortic wall weakness (71).
Congenital mitral valve stenosis is a rare lesion. Balloon
ngioplasty is a well-known treatment modality for treat-
ent of rheumatic mitral valve stenosis (72). However, the
pplication of this technique in cases of congenital mitral
alve stenosis is limited with a low success rate.
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608ight-Sided Obstructive Lesions
he overall frequency of peripheral arterial pulmonic ste-
osis is 2% to 3% of all CHD. It either is an isolated lesion
r associated with other cardiac defects, such as VSD,
etralogy of Fallot, PDA, and ASD. The lesion is common
n certain syndromes, such as rubella, Williams, Noonan,
lagille, Ehlers-Danlos, cutis laxa, LEOPARD, and Silver-
ussell syndromes (73–75).
Patients with mild to moderate arterial obstruction are
sually asymptomatic. Cases with severe stenosis may have
yspnea on exertion, easy fatigability, and occasional right-
ided heart failure. Treatment of pulmonary artery stenosis
epends on the site of the stenotic segment. Percutaneous
ulmonary angioplasty is suitable for distal lesions unreach-
ble by surgery, and surgical pulmonary arterioplasty is
easible for more proximal lesions.
Variable modalities of percutaneous treatment regimens
nclude balloon pulmonary angioplasty, cutting balloons,
nd intravascular stent placement.
Balloon pulmonary angioplasty was first described by
artin et al. (76) to treat peripheral pulmonary stenosis in
post-operative 18-year-old after repair of pulmonary
tresia with VSD. Despite advances in balloon types and
ressure achieved, around one-third of vessels, more often
istal, remain resistant to angioplasty (77).
The use of cutting balloons is an effective treatment for
mall lobar pulmonary artery stenosis refractory to currently
vailable techniques (78).
Stenting of branch pulmonary arteries is frequently used
n children with pulmonary artery stenosis and/or hypopla-
Figure 4. Cine Fluoroscopic Images in the Lateral Projection in a 6-Year-Ol
(A) Angiogram in the aortic arch demonstrating the presence of tight coarctat
(B) Repeat angiogram in the arch after deployment of a P2510 Genesis stent m
New York) then further dilated with a 12 mm  2.5 cm Tyshak balloon. This a
the ﬁnal gradient was 4 mm Hg.ia (79–81). Due to the higher immediate success and lower tncidence of restenosis, stenting of pulmonary arteries may
e a reasonable first-line therapy.
Intraoperative intravascular stent placement is a hybrid
echnique that could be used in difficult situations. It is
uitable in early post-operative period, difficult vascular
natomy, bilateral stenoses requiring simultaneous stent
mplantation, short proximal segment stenosis (too short for
he shortest stent available), marginal hemodynamics, severe
ilateral branch stenosis, patients on extracorporeal mem-
rane oxygenation, and patients with other cardiac lesions
equiring surgery (82).
iscellaneous Lesions Requiring
ercutaneous Intervention
atients after Fontan operation. Often a fenestration is
reated between the inferior vena caval pathway and the
ody of the right atrium to allow decompression to the
ystemic circuit. In the longer term, there may be a
ignificant right-to-left shunt through such fenestrations,
ausing systemic hypoxemia and desaturation. Further, such
enestration may predispose the patient to a paradoxical
mbolism. These fenestrations are often amenable to closure
n the cardiac catheter laboratory, using the same type of
evices that would be used to close an ASD (83).
ortopulmonary collaterals. Collateral vessels occur in a
ide variety of conditions, including pulmonary atresia with
SD, tetralogy of Fallot, scimitar syndrome, and in hearts
ndergoing Fontan-type reconstruction. They may be arte-
ial or venous and may shunt left to right or right to left. As
e Child With Severe COA With a Gradient of 31 mm Hg
the aorta (COA) (arrow). The narrowest diameter measures 2.5 mm.
ed initially over a 9 mm  2 cm Z-MED balloon (NuMED Inc., Hopkinton,
ram demonstrates good stent position with a ﬁnal diameter of 9 mm andd Mal
ion of
ount
ngioghey are often difficult for the surgeon to access, they may be
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609ccluded with coils or occluder devices in the cardiac
atheter laboratory (84).
For an aortopulmonary collateral vessel to be occluded, it
ust supply a segment of the pulmonary arterial tree that
eceives dual arterial supply and must not be required for
dequate systemic arterial oxygen content.
onduit obstruction. Extracardiac conduits may be used to
onnect the subpulmonary ventricle to the pulmonary arter-
es in patients with complex congenital disease. These
onduits can develop obstruction secondary to severe angu-
ation, calcification, sternal compression, or tissue prolifer-
tion, mainly at anastomotic sites. Restenosis is common
fter balloon angioplasty procedures. Stent implantation has
emonstrated better long-term outcome, yet with recog-
ized risks (85). Risks include stent fracture, limitation of
he ability of future surgical conduit replacement, severe
egurgitation in valved conduits, and coronary artery
ompression.
fter tetralogy of Fallot repair. Tetralogy of Fallot accounts
or 3.5% of infants born with CHD. Pulmonary regurgita-
ion, residual peripheral arterial pulmonic stenosis, and
mall residual VSDs are common after surgical repair of
etralogy of Fallot.
The use of balloon angioplasty and the cutting balloon
as been successful in releasing residual peripheral arterial
ulmonic stenoses that are usually more distal than the
urgeons can reach. Percutaneous intravascular stent place-
ent has been very successful and avoids restenosis that
ccurs due to the elastic recoil of the arteries. In situations
here a significant residual defect is noticed, percutaneous
evice closure may take place if feasible technically.
Pulmonary regurgitation is common following repair of
etralogy of Fallot. Although well tolerated for some years,
ormal exercise testing shows a negative correlation between
ulmonary regurgitant fraction measured angiographically
nd exercise ability (86). The effects of pulmonary regurgi-
ation include atrial arrhythmias, heart failure, prolonged
RS interval duration, increased risk of malignant ventric-
lar arrhythmias, and increased risk of sudden death.
Surgery was the only available option for treatment of
ost-operative pulmonary regurgitation until Bonhoeffer et
l. (87) reported the first successful animal experience with
ercutaneous pulmonary valve implantation. Many success-
ul reports of percutaneous pulmonary valve replacement
ollowed then with encouraging results. Unresolved issues
emain, including valve durability, stent fracture, device
mbolization, adjacent structure impingement, limited valve
ize, recurrent regurgitation and stenosis, and the need for
arge catheters for delivery (88). Modifications of current
echnique of percutaneous pulmonary valve placement have
een suggested to allow using the percutaneous valves in
ight ventricular outflow tracts larger than 22 mm. The
uggested hybrid approach includes banding the main pul-
onary artery surgically to 18 mm then placement of thetent-mounted bovine jugular venous valve by either an
off-pump” transventricular approach or a percutaneous
pproach (89,90). Right ventricular outflow tract reducers
re being developed so that percutaneous valve implantation
ill be possible (91).
ummary
ercutaneous intervention in pediatric cardiac disease had
eveloped in the past 3 decades. There are devices approved
or percutaneous closure of ASDs, PDAs, and muscular
SDs. The era of percutaneous valve implantation is just
eginning, and we suspect the next few years will witness
he development of miniaturized valve delivery systems to
nable implantation in smaller children.
Performing interventional cardiac catheterization in chil-
ren requires high skills and training. Only trained pediat-
ic/congenital cardiologists with expertise in interventional
herapy should perform such complex procedures. Fully
quipped catheterization laboratory, surgical backup, and
xtracorporeal membrane oxygenation support capabilities
hould be available in any center planning to perform
nterventional cardiac catheterization.
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